biostudies-literatureYau KCOVID-19 Immunity Task Force20543581231160511https://www.ebi.ac.uk/biostudies/studies/S-EPMC10028441biostudies-literatureUnknown10<h4>Background</h4>People living with chronic kidney disease (CKD) have been disproportionately affected by the coronavirus disease 2019 (COVID-19) pandemic, including higher rates of infection, hospitalization, and death. Data on responsiveness to COVID-19 vaccination strategies and immunogenicity are limited, yet required to inform vaccination strategies in this at-risk population.<h4>Objective</h4>The objective of this study is to characterize the longitudinal serologic response to COVID-19 vaccination.<h4>Design</h4>This is a prospective observational cohort study.<h4>Setting</h4>Participating outpatient kidney programs within Ontario and British Columbia.<h4>Patients</h4>Up to 2500 participants with CKD G3b-5D receiving COVID-19 vaccination, including participants receiving dialysis aCanadian journal of kidney health and diseaseDetermining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol.PMC10028441No. 2122-HQ-000071Siwakoti AHladunewich MATran VDhruve MEnilama OKozak RRomney MGLeis JAChan CTLevin AColwill KYau KKandel COliver MJBlake PPerl JSinger JTsui HBolotin SAbe KTEstrada-Codecido JHu QTam PBrown TGingras ACfalseDetermining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol.<h4>Background</h4>People living with chronic kidney disease (CKD) have been disproportionately affected by the coronavirus disease 2019 (COVID-19) pandemic, including higher rates of infection, hospitalization, and death. Data on responsiveness to COVID-19 vaccination strategies and immunogenicity are limited, yet required to inform vaccination strategies in this at-risk population.<h4>Objective</h4>The objective of this study is to characterize the longitudinal serologic response to COVID-19 vaccination.<h4>Design</h4>This is a prospective observational cohort study.<h4>Setting</h4>Participating outpatient kidney programs within Ontario and British Columbia.<h4>Patients</h4>Up to 2500 participants with CKD G3b-5D receiving COVID-19 vaccination, including participants receiving dialysis a2023-01-01T00:00:00Z20232026-05-28T10:58:48.712Z2024-11-05T18:06:54.621ZS-EPMC100284413695002810.1177/20543581231160511